Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

2.

ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.

Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C.

Int J Mol Sci. 2019 May 21;20(10). pii: E2505. doi: 10.3390/ijms20102505. Review.

3.

Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.

Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, Comunanza V, Alexa-Stratulat T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C.

Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32419. [Epub ahead of print]

PMID:
31107974
4.

Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?

Kopecka J, Gazzano E, Castella B, Salaroglio IC, Mungo E, Massaia M, Riganti C.

Semin Cell Dev Biol. 2019 May 18. pii: S1084-9521(18)30164-2. doi: 10.1016/j.semcdb.2019.05.008. [Epub ahead of print] Review.

PMID:
31100351
5.

Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.

Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardissone F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C.

J Thorac Oncol. 2019 Aug;14(8):1458-1471. doi: 10.1016/j.jtho.2019.03.029. Epub 2019 May 9.

6.

Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.

Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C.

Cancer Lett. 2019 Aug 1;456:29-39. doi: 10.1016/j.canlet.2019.04.029. Epub 2019 Apr 29.

PMID:
31047947
7.

Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.

Mujumdar P, Kopecka J, Bua S, Supuran CT, Riganti C, Poulsen SA.

J Med Chem. 2019 Apr 25;62(8):4174-4192. doi: 10.1021/acs.jmedchem.9b00282. Epub 2019 Apr 10.

PMID:
30925064
8.

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J.

J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.

9.

Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.

Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, Rolando B, Fruttero R, Gasco A, Hattinger C, Serra M, Riganti C.

Cell Mol Life Sci. 2019 Feb;76(3):609-625. doi: 10.1007/s00018-018-2967-9. Epub 2018 Nov 14.

PMID:
30430199
10.

Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.

Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C.

Mol Cancer Ther. 2018 Dec;17(12):2598-2609. doi: 10.1158/1535-7163.MCT-18-0533. Epub 2018 Sep 25.

PMID:
30254183
11.

Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells.

Gazzano E, Lazzarato L, Rolando B, Kopecka J, Guglielmo S, Costamagna C, Chegaev K, Riganti C.

Front Pharmacol. 2018 Jun 4;9:580. doi: 10.3389/fphar.2018.00580. eCollection 2018.

12.

New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro.

Salaroglio IC, Gazzano E, Kopecka J, Chegaev K, Costamagna C, Fruttero R, Guglielmo S, Riganti C.

Molecules. 2018 Jun 9;23(6). pii: E1401. doi: 10.3390/molecules23061401.

13.

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.

Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C.

Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26.

PMID:
29748013
14.

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.

Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.

15.

ω-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy.

Corsetto PA, Colombo I, Kopecka J, Rizzo AM, Riganti C.

Int J Mol Sci. 2017 Dec 20;18(12). pii: E2770. doi: 10.3390/ijms18122770. Review.

16.

Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.

Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C.

J Control Release. 2018 Jan 28;270:37-52. doi: 10.1016/j.jconrel.2017.11.042. Epub 2017 Dec 2.

PMID:
29191785
17.

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.

Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, Caruso D, Novelli F, Riganti C, Massaia M.

Nat Commun. 2017 Jun 5;8:15663. doi: 10.1038/ncomms15663.

18.

PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.

Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, Kopecka J, Riganti C.

Mol Cancer. 2017 May 12;16(1):91. doi: 10.1186/s12943-017-0657-0.

19.

Intermittent bilateral coherence in physiological and essential hand tremor.

Chakraborty S, Kopecká J, Šprdlík O, Hoskovcová M, Ulmanová O, Růžička E, Zapotocky M.

Clin Neurophysiol. 2017 Apr;128(4):622-634. doi: 10.1016/j.clinph.2016.12.027. Epub 2017 Jan 14.

PMID:
28231479
20.

Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1.

Pati ML, Groza D, Riganti C, Kopecka J, Niso M, Berardi F, Hager S, Heffeter P, Hirai M, Tsugawa H, Kabe Y, Suematsu M, Abate C.

Pharmacol Res. 2017 Mar;117:67-74. doi: 10.1016/j.phrs.2016.12.023. Epub 2016 Dec 19.

PMID:
28007569
21.

Polypyrrole Nanotubes and Their Carbonized Analogs: Synthesis, Characterization, Gas Sensing Properties.

Kopecká J, Mrlík M, Olejník R, Kopecký D, Vrňata M, Prokeš J, Bober P, Morávková Z, Trchová M, Stejskal J.

Sensors (Basel). 2016 Nov 15;16(11). pii: E1917.

22.

P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.

Kopecka J, Rankin GM, Salaroglio IC, Poulsen SA, Riganti C.

Oncotarget. 2016 Dec 27;7(52):85861-85875. doi: 10.18632/oncotarget.13040.

23.

Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.

Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, Hattinger CM, Deaglio S, Kelley SO, Serra M, Riganti C.

Mol Cancer Ther. 2016 Nov;15(11):2640-2652. Epub 2016 Jul 27.

24.

Multi-walled carbon nanotubes directly induce epithelial-mesenchymal transition in human bronchial epithelial cells via the TGF-β-mediated Akt/GSK-3β/SNAIL-1 signalling pathway.

Polimeni M, Gulino GR, Gazzano E, Kopecka J, Marucco A, Fenoglio I, Cesano F, Campagnolo L, Magrini A, Pietroiusti A, Ghigo D, Aldieri E.

Part Fibre Toxicol. 2016 Jun 1;13(1):27. doi: 10.1186/s12989-016-0138-4.

25.

Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.

Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De Rosa G, Caraglia M, Riganti C.

Oncotarget. 2016 Apr 12;7(15):20753-72. doi: 10.18632/oncotarget.8012.

26.

Comparison of DNA-based techniques for differentiation of production strains of ale and lager brewing yeast.

Kopecká J, Němec M, Matoulková D.

J Appl Microbiol. 2016 Jun;120(6):1561-73. doi: 10.1111/jam.13116. Epub 2016 Apr 4.

27.

Effects of Chrysotile Exposure in Human Bronchial Epithelial Cells: Insights into the Pathogenic Mechanisms of Asbestos-Related Diseases.

Gulino GR, Polimeni M, Prato M, Gazzano E, Kopecka J, Colombatto S, Ghigo D, Aldieri E.

Environ Health Perspect. 2016 Jun;124(6):776-84. doi: 10.1289/ehp.1409627. Epub 2015 Dec 18.

28.

Screening for new brewing yeasts in the non-Saccharomyces sector with Torulaspora delbrueckii as model.

Michel M, Kopecká J, Meier-Dörnberg T, Zarnkow M, Jacob F, Hutzler M.

Yeast. 2016 Apr;33(4):129-44. doi: 10.1002/yea.3146. Epub 2016 Jan 21.

29.

Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.

Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Giordano A, Desiderio V, Ghigo D, Caraglia M, De Rosa G, Riganti C.

Oncotarget. 2015 Oct 13;6(31):31461-78. doi: 10.18632/oncotarget.5058.

30.

An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.

Campia I, Buondonno I, Castella B, Rolando B, Kopecka J, Gazzano E, Ghigo D, Riganti C.

PLoS One. 2015 May 8;10(5):e0126159. doi: 10.1371/journal.pone.0126159. eCollection 2015.

31.

The role of C/EBP-β LIP in multidrug resistance.

Riganti C, Kopecka J, Panada E, Barak S, Rubinstein M.

J Natl Cancer Inst. 2015 Mar 11;107(5). pii: djv046. doi: 10.1093/jnci/djv046.

PMID:
25766403
32.

Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.

Kopecka J, Campia I, Jacobs A, Frei AP, Ghigo D, Wollscheid B, Riganti C.

Oncotarget. 2015 Mar 30;6(9):6776-93.

33.

Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein.

Riganti C, Gazzano E, Gulino GR, Volante M, Ghigo D, Kopecka J.

Cancer Lett. 2015 May 1;360(2):219-26. doi: 10.1016/j.canlet.2015.02.008. Epub 2015 Feb 11.

PMID:
25681670
34.

Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.

Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, Riganti C.

Oncotarget. 2015 Jan 20;6(2):1128-42.

35.

Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate.

Melenovská P, Kopecká J, Krijt J, Hnízda A, Raková K, Janošík M, Wilcken B, Kožich V.

J Inherit Metab Dis. 2015 Mar;38(2):287-94. doi: 10.1007/s10545-014-9781-9. Epub 2014 Oct 21.

PMID:
25331909
36.

Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.

Pedrini I, Gazzano E, Chegaev K, Rolando B, Marengo A, Kopecka J, Fruttero R, Ghigo D, Arpicco S, Riganti C.

Mol Pharm. 2014 Sep 2;11(9):3068-79. doi: 10.1021/mp500257s. Epub 2014 Jul 30.

37.

The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells.

Pinzón-Daza ML, Salaroglio IC, Kopecka J, Garzòn R, Couraud PO, Ghigo D, Riganti C.

J Cereb Blood Flow Metab. 2014 Aug;34(8):1258-69. doi: 10.1038/jcbfm.2014.100. Epub 2014 Jun 4.

38.
39.

Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition.

Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, Gazzano E, Ghigo D, Rizzo AM, Riganti C.

Mol Cancer. 2013 Nov 13;12:137. doi: 10.1186/1476-4598-12-137.

40.

Flow sorting and sequencing meadow fescue chromosome 4F.

Kopecký D, Martis M, Číhalíková J, Hřibová E, Vrána J, Bartoš J, Kopecká J, Cattonaro F, Stočes Š, Novák P, Neumann P, Macas J, Šimková H, Studer B, Asp T, Baird JH, Navrátil P, Karafiátová M, Kubaláková M, Šafář J, Mayer K, Doležel J.

Plant Physiol. 2013 Nov;163(3):1323-37. doi: 10.1104/pp.113.224105. Epub 2013 Oct 4.

41.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

42.

Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier.

Pinzón-Daza ML, Campia I, Kopecka J, Garzón R, Ghigo D, Riganti C.

Curr Drug Metab. 2013 Jul;14(6):625-40. Review.

PMID:
23869808
43.

Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition.

Kopecka J, Salzano G, Campia I, Lusa S, Ghigo D, De Rosa G, Riganti C.

Nanomedicine. 2014 Jan;10(1):77-87. doi: 10.1016/j.nano.2013.06.013. Epub 2013 Jul 10.

44.

Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.

Riganti C, Salaroglio IC, Pinzòn-Daza ML, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Couraud PO, Bosia A, Ghigo D, Schiffer D.

Cell Mol Life Sci. 2014 Feb;71(3):499-516. doi: 10.1007/s00018-013-1397-y. Epub 2013 Jun 15.

45.

Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.

Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M.

PLoS One. 2013 Apr 12;8(4):e60975. doi: 10.1371/journal.pone.0060975. Print 2013.

46.

Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance.

Riganti C, Rolando B, Kopecka J, Campia I, Chegaev K, Lazzarato L, Federico A, Fruttero R, Ghigo D.

Mol Pharm. 2013 Jan 7;10(1):161-74. doi: 10.1021/mp300311b. Epub 2012 Dec 7.

47.

Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes.

Campia I, Sala V, Kopecka J, Leo C, Mitro N, Costamagna C, Caruso D, Pescarmona G, Crepaldi T, Ghigo D, Bosia A, Riganti C.

Biochem J. 2012 Oct 15;447(2):301-11.

PMID:
22845468
48.

Selective increase in blood dendritic cell antigen-3-positive dendritic cells in bronchoalveolar lavage fluid in allergic patients.

Kayserova J, Zentsova-Jaresova I, Budinsky V, Rozkova D, Kopecka J, Vernerova E, Pohunek P, Skalicka V, Spisek R, Sediva A.

Scand J Immunol. 2012 Mar;75(3):305-13. doi: 10.1111/j.1365-3083.2011.02649.x.

49.

Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.

Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, Ghigo D.

Biochem J. 2011 Oct 1;439(1):141-9. doi: 10.1042/BJ20102016.

PMID:
21679161
50.

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.

Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A.

Mol Pharm. 2011 Jun 6;8(3):683-700. doi: 10.1021/mp2001389. Epub 2011 May 5.

PMID:
21491921

Supplemental Content

Loading ...
Support Center